#United States #Sapience Therapeutics #Pamela Esposito #Augustine Bourne #Tarrytown

Enhancing Leadership for Strategic Growth at Sapience Therapeutics

Sapience Therapeutics, Inc., a clinical-stage biotechnology firm dedicated to peptide therapeutics, announced significant leadership enhancements aimed at accelerating its growth in the oncology sector. On December 5, 2024, the company revealed the appointments of Pamela Esposito, Ph.D., to its Board of Directors, and Augustine Bourne as Vice President of Business Development. These strategic additions signal Sapience's commitment to expanding its innovative pipeline that addresses severe cancers while driving corporate growth.

New Board Appointments: Expertise and Vision

Pamela Esposito, an accomplished business strategist with over two decades of experience, joins the board, bringing a wealth of knowledge in business development and leadership in the biotech field. Previously, Dr. Esposito served as the Chief Business Officer of Replimune, where she played a pivotal role in securing nearly $1 billion in funding. Her track record includes leading transformative commercial strategies at Ra Pharmaceuticals, which was acquired for approximately $2.7 billion, and contributing significantly to Mariana Therapeutics' acquisition by Novartis.

Dr. Esposito expressed enthusiasm about her new role, emphasizing the promise of Sapience’s peptide platform to create first-in-class therapies targeting traditionally untreatable cancer drivers. This excitement reflects a growing belief within the industry that novel therapeutic approaches, such as peptide-based interactions, can provide new avenues for addressing complex oncogenic mechanisms.

In addition to Dr. Esposito, Augustine Bourne brings to the team over 15 years of strategic development in the biotech sector. Prior to his role at Sapience, he led business development initiatives at Mirati Therapeutics, a company that experienced remarkable growth before being acquired by Bristol Myers Squibb. Bourne's extensive experience at Regeneron bolstered his adept skills in navigating the complexities of corporate strategy within oncology pipelines, making him a valuable asset for Sapience’s growth trajectory.

Strategic Goals and Future Directions

Dr. Barry Kappel, CEO and President of Sapience, expressed his excitement about these new appointments, noting that their combined expertise is essential as the company nears critical advances in its key programs—ST316, targeting β-catenin in colorectal cancer, and the innovative lucicebtide for glioblastoma, which is currently under Phase 2 clinical trials. The robust pipeline not only enhances Sapience's strategic direction but also aims to fulfill a pressing need for effective cancer therapies in a market characterized by unmet medical needs.

Both Dr. Esposito and Mr. Bourne emphasized the significance of their dual roles within the context of ongoing collaborations and strategic partnerships that can leverage their extensive networks and operational insights. They are poised to drive value across multiple stakeholders, including patients, healthcare providers, and investors.

Conclusion

As Sapience Therapeutics moves forward, the integration of seasoned professionals like Dr. Esposito and Mr. Bourne highlights its pursuit of pioneering solutions in oncology. The company's focus on developing therapeutics that target complex protein interactions aims to redefine treatment strategies in the industry, promising a new era in cancer care. As they embark on this transformative journey, the leadership team remains committed to innovation, strategic growth, and the relentless pursuit to meet the needs of patients battling cancer.

For more information on Sapience Therapeutics and its ongoing efforts to pioneer peptide therapeutics, visit the official website and connect on LinkedIn.